Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Search content at Prinses Máxima Centrum
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Who benefits most from adjuvant interferon treatment for melanoma?
Helen Gogas
, Huseyin Abali
, Paolo A. Ascierto
, Lev Demidov
, Hubert Pehamberger
, Caroline Robert
, Jacob Schachter
,
Alexander M.M. Eggermont
, Axel Hauschild
, Enrique Espinosa
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
15
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Who benefits most from adjuvant interferon treatment for melanoma?'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Adjuvant Therapy
100%
Melanoma
100%
Interferon Treatment
100%
Adjuvant Interferon
100%
Interferon-α (IFN-α)
75%
Tolerability
50%
Metastatic Melanoma
50%
Treatment Decisions
25%
Patient Selection
25%
Molecular Profile
25%
Patient Benefit
25%
Poor Prognosis
25%
Cytokine Profile
25%
Effective Compounds
25%
Median Survival
25%
Disease-free Survival
25%
Primary Lesion
25%
Breslow Thickness
25%
Stage IV Melanoma
25%
Positive Lymph Node Ratio
25%
Interferon Therapy
25%
American Joint Commission on Cancer
25%
Guide Selection
25%
Staging Criteria
25%
Emerging Biomarkers
25%
Cost-benefit
25%
Side Effect Profile
25%
Biomarker Data
25%
Immunologic Markers
25%
Medicine and Dentistry
Interferon
100%
Melanoma
100%
Adjuvant Therapy
80%
Malignant Neoplasm
20%
Biological Marker
20%
Disease
20%
Cytokine
20%
Side Effect
20%
Cost Benefit Analysis
20%
Lymph Node
20%
Disease Free Survival
20%
Metastatic Melanoma
20%
Nursing and Health Professions
Melanoma
100%
Interferon
100%
Adjuvant Therapy
80%
Disease
20%
Malignant Neoplasm
20%
Side Effect
20%
Biological Marker
20%
Cost Benefit Analysis
20%
Disease Free Survival
20%
Metastatic Melanoma
20%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Interferon
100%
Tolerability
40%
Malignant Neoplasm
20%
Biological Marker
20%
Disease
20%
Side Effect
20%
Cytokine
20%
Disease Free Survival
20%
Metastatic Melanoma
20%